



The transformative CRISPR-Cas9 technology: A bacterial mechanism

Emmanuelle Charpentier's Laboratory




CRISPR-Cas: RNA-mediated adaptive immune system in bacteria and archaea

CRISPR: clustered, regularly interspaced short palindromic repeats

Cas: CRISPR-associated

Infection of bacteria by invading genomes

Mobile Genetic Elements




attack




defence

Bacterial Host



Infection of bacteria by invading genomes

Mobile Genetic Elements




attack




defence



Bacterial Host



Lytic Cycle



Lysogenic Cycle




phage

invading
DNA


bacterial
DNA

The CRISPR-Cas adaptive immune system




Bacterial pathogens

Streptococcus pyogenes = Group A streptococcus




Manfred Rohde (HZI, Braunschweig)

Type II CRISPR-Cas: crRNA maturation




Type II CRISPR-Cas: DNA interference



CRISPR-Cas9 technology: a two-component system


The enzyme Cas9 is programmed with a guide RNA to target and cleave specifically DNA



Important milestones towards gene therapy

Fundamental genetics

“Rules”



1859
Darwin “On the Origin of Species”



1865
Mendel – Laws of segregation of alleles



1871
Miescher – Isolation of DNA

Structure



1953
Watson, Crick, Franklin & Wilkins
Structure of double-helix of DNA




1966
Genetic code is revealed

Genetic tools

“Basics”

Mid-1970's
Restriction enzymes
Recombinant DNA



1977
Sanger Sequencing



1983-88
Invention and development of PCR

Gene editing



1996
Zinc finger nucleases




2010
TALENs

Important milestones towards gene therapy

Fundamental genetics

“Rules”



1859
Darwin “On the Origin of Species”



1865
Mendel – Laws of segregation of alleles



1871
Miescher – Isolation of DNA

Structure



1953
Watson, Crick, Franklin & Wilkins
Structure of double-helix of DNA




1966
Genetic code is revealed


Genetic tools

“Basics”

Mid-1970's
Restriction enzymes
Recombinant DNA




1977
Sanger Sequencing



1983-88
Invention and development of PCR

Possible to introduce changes, but time-consuming and difficult


Gene editing




2012
CRISPR-Cas9

Fast and easy tool needed

Genome editing with sequence-specific nucleases



RNA-programmable CRISPR-Cas9





RNA-programmed Cas9 could offer considerable potential for genome editing in cells of the three kingdoms of life for biotechnological, biomedical and gene-therapeutic purposes.

- **Advantages:**


- Cheap and easy
- Efficient
- Versatile
- Multiplexing
- Various flavors

- **Improvements:**

- Specificity (off-target)
- Toxicity
- Delivery



tracrRNA is associated to type II CRISPR-Cas





Interchangeability among dual-RNA-Cas9 orthologs



Dual RNA

Cas9


F. novicida



S. pyogenes





S. mutans




*S. thermophilus**





*S. thermophilus***




N. meningitidis



P. multocida



C. jejuni



Applications of CRISPR-Cas9 in biology



Human medicine

Agriculture: crops

Synthetic biology:
pathway engineering

Applications of CRISPR-Cas9 in human medicine



Human medicine

- Understanding of functions of genes and unravel new pathways
- Engineering of disease models
- Screening for new targets for therapeutics
- Validation of new therapeutic targets and medicine under development
- Bed to bench approach (e.g. genetic predisposition for diseases)
- Develop direct therapeutics (e.g. gene therapy)



The transformative CRISPR-Cas9 technology: A bacterial mechanism

Emmanuelle Charpentier's Laboratory



CRISPR-Cas9: Funding

Austria



CRISPR-Cas9: Funding

Sweden



Vetenskapsrådet

EMBL



CRISPR-Cas9: Funding

Sweden



Vetenskapsrådet

EMBL



Germany



MAX-PLANCK-GESELLSCHAFT

Unterstützt von / Supported by



Alexander von Humboldt
Stiftung / Foundation



Bundesministerium
für Bildung
und Forschung





The transformative CRISPR-Cas9 technology: A bacterial mechanism

Emmanuelle Charpentier's Laboratory



